Emcure Pharmaceuticals

Emcure Pharmaceuticals reported a sharp 48 percent year-on-year increase in net profit to Rs. 231 crore for the third quarter, reflecting robust operational execution and favorable demand trends across key markets. The strong performance was supported by improved revenue mix, cost efficiencies, and steady growth in domestic and international formulations. The results underscore Emcure’s ability to navigate pricing pressures and regulatory complexities while sustaining earnings momentum.

Emcure Pharmaceuticals has entered into a strategic partnership with Sanofi India to market and distribute Sanofi’s well-established anti-diabetic portfolio across the country. The collaboration is set to significantly enhance Emcure’s presence in the burgeoning diabetes care segment, while enabling Sanofi to widen the reach of its trusted brands. This alliance comes at a time when India faces an alarming surge in diabetes prevalence, creating a pressing need for greater access to quality therapies.